(UroToday.com) Sitravatinib is a tyrosine kinase inhibitor that inhibits multiple proteins including TAM (Tyro3, Axl, Mer) receptors, KIT and VEGFR2. Preclinical evidence suggests that sitravatinib may promote an anti-tumor immune response by reducing myeloid-derived suppressor cells and Tregs in the tumor microenvironment.